T. Rowe Price launches Biotech active equity ETF on Nasdaq under TDNA

• T. Rowe Price launched three active equity ETFs on Nasdaq: TDNA, TSEE, TMID, expanding its active ETF lineup to 38 funds.
• TDNA targets long-term capital growth in biotechnology; expected to hold 60-120 stocks; expense ratio 0.55%.
• TSEE provides diversified U.S. small-cap exposure; typically holds 200+ stocks; expense ratio 0.59%.
• TMID is an actively managed core U.S. mid-cap strategy; typically holds 300+ stocks; expense ratio 0.47%.
• The launches bring the firm’s new active ETFs this year to eight, broadening coverage across equity segments.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. T. Rowe Price Group Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202609170958PR_NEWS_USPR_____PH50171) on September 17, 2026, and is solely responsible for the information contained therein.